J DermatolClinical trial
Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis
5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.
From the abstractYear 1 response rates were also maintained through Year 5 in PSO-4 patients and in PSO-1 patients who crossed over from placebo. These findings support the long-term safety and durable efficacy profile of deucravacitinib through 5 years in Japanese patients with psoriasis.
Okubo Y, Morita A, … senior author Ohtsuki MJournal of Dermatology